Background: Coronavirus disease 2019 (COVID-19)–related critical illness and acute illness
are associated with a risk of venous thromboembolism (VTE). Objective: These evidence-…

In response to the COVID-19 pandemic, vaccines for SARS-CoV-2 were developed, tested,
and introduced at a remarkable speed. Although the vaccine introduction had a major impact …

Background Despite advances in treatment options for thrombotic thrombocytopenic purpura
(TTP), there are still limited high quality data to inform clinicians regarding its appropriate …

Background Despite an increase in our understandings of pathogenesis of thrombotic
thrombocytopenic purpura (TTP), the approaches for initial diagnosis and management of TTP …

Vaccine‐induced immune thrombotic thrombocytopenia (VITT) is a rare but severe immunological
reaction to the non‐replicable adenoviral vector‐based COVID‐19 vaccines. Extreme …

Direct oral anticoagulants (DOACs) are attractive options for treatment of heparin-induced
thrombocytopenia (HIT). We report our continuing experience in Hamilton, ON, Canada, since …

Objectives: To identify risk factors for failure of anticoagulant thromboprophylaxis in critically
ill patients in the ICU. Design: Multivariable regression analysis of thrombosis predictors …

The impact of transfusing fresher vs older red blood cells (RBCs) on patient-important outcomes
remains controversial. Two recently published large trials have provided new evidence. …

… PAI-1 antigen and u-PA–PAI-1 complexes using ELISA. QPD platelets contained approximately
2-fold more PAI-1 antigen and more than 100-fold more u-PA–PAI-1 … some of the PAI-1 in …

BACKGROUND Information about patient survival after transfusion of multiple blood
volumes is limited, and most reports have focused on trauma patients. STUDY DESIGN AND …